Table 1.
Baseline characteristics of the patients with inv(3)(q21q26) and/or 46,XX,t(3;3)(q21;q26).
| # | Age/gender | Diagnosis | WBC | Blast | Hb | Plat | Karyotype [12] | Outcome |
|---|---|---|---|---|---|---|---|---|
| WHO 2008 AML with inv(3)(q21q26.2) | ||||||||
| 1 | 55/M | AML-M4 | 9.8 | 7 | 10 | 197 | 46,XY,inv(3)(q21q26)[21] | DC/11mos |
| 2 | 87/M | AML-M0 | 21.1 | 15.4 | 10 | 64 | 46,XY,inv(3)(q21q26)[21] | DC/1mos |
| 3 | 48/F | AML-M4 | 10.5 | 7.6 | 8.9 | 203 | 45,XX,inv(3)(q21q26),−7[16]/46,XX[4] | DC/8mos |
| 4 | 66/F | AML-M0 | 14 | 12.6 | 9.9 | 92 | 46,XX,inv(3)(q21q26),del(5)(q13q33)[21] | DC/1mos |
| 5 | 28/F | AML | 3.9 | 0 | 8.4 | 27 | 46,XY,inv(3)(q21q26.2)[20] | Rel/23 mos |
| 6 | 39/F | AML | 14.2 | 4.8 | 13 | 346 | 45,XY,inv(3)(q21q26.2),del(5)(q22q31),−7[19] | DC/5mos |
| 7 | 78/F | AML-M4 | 95 | 86 | 11 | 45 | 46,XX,t(3;3)(q21;q26)[15] | DC/1mos |
| 8 | 51/M | AML-M1 | 3.8 | 0 | 7.5 | 195 | 45,XY,t(3;3)(q21;q26),−7[10] | DC/6mos |
| References | ||||||||
| 3 | 53/F | AML-M2 | 6.2 | 1.3 | 9.5 | 62 | 46,XX,inv(3)[4]/45,idem,−7[28] | DC/11mos |
| 3 | 20/M | AML-M4 | 438 | 221 | 5.6 | 179 | 45,XY,inv(3),−7[12]/46,XY[3] | DC/12mos |
| 5 | 55/M | AML-M0 | 2.9 | 0.45 | 6.1 | 36 | 45,XY,inv(3)(q21q26),−7[18]/46,XY[3] | DC/10mos |
| 6 | 53/M | AML | 4 | 0.42 | 8.4 | 58 | 45,XY,inv(3)(q21q26),−7[20] | DC/1mos |
| 7 | 31/M | AML | 8.8 | 1.2 | 13.6 | 206 | 46,XXY,inv(3)(q21q26),−7[18]/47,XXY[2] | DC/2mos |
| 8 | 37/F | AML-M0 | 9.5 | 6.7 | N/A | 903 | 45,XX,der(6)ins(6;3)(q23;q21q26)inv(3)(q21q26),−7[25] | Rel/2mos |
| 9 | 48/F | AML-M4 | 5.8 | 1.4 | 9.7 | 63 | 46,XX,inv(3)(q21q26)[10]/45,idem,−7[7]/46,XX[3] | DC/11mos |
| Inv(3)(q21q26.2)-containing blasts | ||||||||
| 9 | 29/M | CML-BP | 7.9 | 0.2 | 14 | 449 | 46,XY,inv(3)(q21q26.2),t(9;22)(q34;q11.2)[20] | DC/9mos |
| 10 | 70/M | MMM | 30.7 | 6 | 9.7 | 61 | 46,XY,inv(3)(q21q26)[5] | DC/1mos |
| 11 | 70/F | s-AML | 3.5 | 0.9 | 9.2 | 165 | 45,XX,inv(3)(q21q26),−7[4]/46,XX[1] | DC/7mos |
| 12 | 62/M | CML-BP | 51.5 | 39 | 9.6 | 622 | 46,XY,inv(3)(q21q26),t(9;22)(q34;q11.2)[3] | DC/12mos |
| 13 | 21/F | s-AML | 1.5 | 0.3 | 6.4 | 108 | 46,XX,inv(3)(q21q26)[17]/46,idem,−7, +mar[3] | DC/16mos |
| 14 | 23/M | t-AML | 1.8 | 0.2 | 13 | 33 | 46,XY,inv(3)(q21q26),t(6;12)(q12;q24)[13]/46XY[8] | DC/24mos |
| References | ||||||||
| 3 | 32/M | s-AML | 64.7 | 39 | 6.7 | 477 | 45,XY,inv(3),−7[21]/46,XY[4] | DC/12mos |
| 3 | 63/F | s-AML | 8.7 | 8 | 11 | 112 | 45,XY,inv(3),−7[18]/46,XY[2] | DC/5mos |
| 3 | 52/M | s-AML | 22.8 | 11 | 10 | 647 | 45,XY,inv(3),−7[8]/46,XY[3] | DC/15mos |
| 3 | 74/M | CML | 13.1 | 1.3 | 8 | 179 | 46,XY,inv(3)[12]/46,XY,idem,t(9;22)[35] | DC/NA |
| 3 | 73/F | s-AML | 1.9 | 0.2 | 6.3 | 181 | 46,XX,der(3)(q21 → p21::q26 → q21::q27 → q29::p21 → p26) del(5)(q13q33)[13]/46,XX[12] |
DC/12mos |
| 6 | 42/F | MDS | N/A | N/A | N/A | N/A | 46,XY,inv(3)(q21q26)[10]/46,XY[3] | DC/20mos |
WBC: white blood cell count (×109 L−1), Blast: peripheral blood absolute leukemia blast count (×109 L−1), Hb: hemoglobin (g/dL), Plat: platelet count (×109 L−1), Rel: relapsed, DC: deceased, MDS: myelodysplasia, MMM: myelofibrosis, CMP-BP: blastic phase chronic myelogenous leukemia, t-AML: therapy-related AML, s-AML: secondary AML.